MK-4618 (Vibegron, KRP-114V, RVT-901) is a potent and selective full β3 adrenergic receptor agonist with EC50 of 1.1 nM.
MK-4618 (Vibegron) displays no activity for β1 and β2 receptors (EC50>20 uM).
MK-4618 (Vibegron) dose-dependently increases bladder capacity, decreased micturition pressure, and increased bladder compliance in rhesus monkeys, dose-dependently increases the circulating glycerol and fatty acid levels in rhesus and rat in vivo.
MK-4618 (Vibegron) shows the potential for treatment of overactive bladder with M2/M3 antimuscarinics.
